Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 98
- Registration Number
- NCT02730091
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 68
- Registration Number
- NCT02709720
- Locations
- 🇪🇸
Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain
🇪🇸Hospital Universitario Lucus Augusti, Lugo, Spain
🇪🇸H. Son Llàtzer, Palma de Mallorca, Spain
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT02665702
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 2
- Registration Number
- NCT02658084
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 248
- Registration Number
- NCT02610140
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 84
- Registration Number
- NCT02607215
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 120
- Registration Number
- NCT02585388
- Locations
- 🇫🇷
CHU de Grenoble, Grenoble, France
🇫🇷CHD Vendée, La Roche sur Yon, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 134
- Registration Number
- NCT02579564
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 529
- Registration Number
- NCT02574455
- Locations
- 🇺🇸
Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States
🇺🇸Souther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States
🇺🇸Southern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 325
- Registration Number
- NCT02567435
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Atrium Health Navicent, Macon, Georgia, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.